Romosozumab

Romosozumab is a monoclonal antibody investigated for bone formation stimulation and bone loss prevention in osteoporosis research. Research suggests it may enhance osteoblast activity while reducing osteoclast function, potentially increasing bone mineral density. This peptide is studied for its unique anabolic effects on bone metabolism.